Adzynma™ (ADAMTS13 recombinant-krhn)

Adzynma is covered for prophylactic or on‑demand enzyme replacement therapy only in adult and pediatric patients with congenital TTP and is excluded for immune‑mediated (acquired) TTP. Coverage requires baseline ADAMTS13 activity <10% (<10 IU/dL) measured before any ADAMTS13‑directed or plasma therapy, absence of anti‑ADAMTS13 autoantibodies, a documented pathogenic ADAMTS13 gene variant, prescribing by or in consultation with a hematologist, authorization up to 12 months, and adherence to specified dosing (prophylaxis 40 IU/kg IV q2wk, may increase to q1wk; on‑demand 40 IU/kg Day 1, 20 IU/kg Day 2, then 15 IU/kg daily until 2 days after resolution).

"Adzynma is indicated for prophylactic or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)."

Sign up to see full coverage criteria, indications, and limitations.